PDCD1 and neoplasm: ICIs are monoclonal antibodies that block down-regulators of adaptive immunity, including cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and its ligand (PD-L1), unleashing effector T-cell activity and reinstating anti-tumor activity [2].